PMID- 16850745
OWN - NLM
STAT- MEDLINE
DCOM- 20080512
LR  - 20191110
IS  - 1672-0733 (Print)
IS  - 1672-0733 (Linking)
VI  - 26
IP  - 2
DP  - 2006
TI  - Effects of simvastatin on NF-kappaB-DNA binding activity and monocyte 
      chemoattractant protein-1 expression in a rabbit model of atherosclerosis.
PG  - 194-8
AB  - To observe the effects of simvastatin on nuclear factor kappaB (NF-kappaB)-DNA 
      binding activity and on the expression of monocyte chemoattractant protein-1 
      (MCP-1) in atherosclerotic plaque in rabbits and to explore the 
      anti-atherosclerotic properties beyond its lipid-lowering effects. Thirty-six New 
      Zealand male rabbits were randomly divided into low-cholesterol group (LC), 
      high-cholesterol group (HC), high-cholesterol+simvastatin group (HC+S) and then 
      were fed for 12 weeks. At the end of the experiment, standard enzymatic assays, 
      electrophoretic mobility shiftassay (EMSA), immunohistochemical staining, and 
      morphometry were performed to observe serum lipids, NF-kappaB-DNA binding 
      activity, MCP-1 protein expression, intima thickness and plaque area of aorta 
      respectively in all three groups. Our results showed that the serum lipids, 
      NF-kappaB-DNA binding activity, expression of MCP-1 protein, intima thickness, 
      and plaque area of aorta in the LC and HC+S groups were significantly lower than 
      those in the HC group (P<0.05). There was no significant difference in the serum 
      lipids between the LC and HC+S groups (P>0.05), but the NF-kappaB-DNA binding 
      activity, the expression of MCP-1 protein and the intima thickness and plaque 
      area of aorta in the HC+S group were significantly decreased as compared to the 
      LC group (P<0.05). This study demonstrated that simvastatin could decrease 
      atherosclerosis by inhibiting the NF-kappaB-DNA binding activity and by reducing 
      the expression of MCP-1 protein.
FAU - Yang, Xiaoyun
AU  - Yang X
AD  - Department of Cardiology, Tongji Medical College, Huazhong University of Science 
      and Technology, Wuhan, China.
FAU - Wang, Lin
AU  - Wang L
FAU - Zeng, Hesong
AU  - Zeng H
FAU - Dubey, Laxman
AU  - Dubey L
FAU - Zhou, Ning
AU  - Zhou N
FAU - Pu, Jun
AU  - Pu J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - J Huazhong Univ Sci Technolog Med Sci
JT  - Journal of Huazhong University of Science and Technology. Medical sciences = Hua 
      zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. 
      Yixue Yingdewen ban
JID - 101169627
RN  - 0 (Chemokine CCL2)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Hypolipidemic Agents)
RN  - 0 (NF-kappa B)
RN  - 97C5T2UQ7J (Cholesterol)
RN  - AGG2FN16EV (Simvastatin)
SB  - IM
MH  - Animals
MH  - Atherosclerosis/metabolism/pathology/*prevention & control
MH  - Chemokine CCL2/*metabolism
MH  - Cholesterol/metabolism
MH  - DNA-Binding Proteins/*metabolism
MH  - Electrophoretic Mobility Shift Assay
MH  - Hypolipidemic Agents/pharmacology/therapeutic use
MH  - Immunohistochemistry
MH  - Male
MH  - NF-kappa B/*metabolism
MH  - Protein Binding/drug effects
MH  - Rabbits
MH  - Random Allocation
MH  - Simvastatin/*pharmacology/therapeutic use
EDAT- 2006/07/21 09:00
MHDA- 2008/05/13 09:00
CRDT- 2006/07/21 09:00
PHST- 2006/07/21 09:00 [pubmed]
PHST- 2008/05/13 09:00 [medline]
PHST- 2006/07/21 09:00 [entrez]
AID - 10.1007/BF02895814 [doi]
PST - ppublish
SO  - J Huazhong Univ Sci Technolog Med Sci. 2006;26(2):194-8. doi: 10.1007/BF02895814.